Compounded vs FDA-Approved HRT: Which Is Right for You?

What "Bioidentical" Actually Means (And What It Doesn't)

The word "bioidentical" describes molecular structure, not regulatory status. A hormone is bioidentical when its chemical structure matches the hormone produced by the human body. Estradiol (17-beta-estradiol), micronized progesterone, and testosterone are all bioidentical by this definition, and they exist in both FDA-approved products and compounded preparations.

This distinction matters because a large segment of direct-to-consumer marketing conflates "bioidentical" with "natural" and "compounded" as if the three terms were synonymous. They are not. Divigel (estradiol 0.1% gel), Climara (estradiol patch), and Prometrium (micronized progesterone 100 mg capsule) are all FDA-approved, bioidentical, and plant-derived. A compounding pharmacy mixing the same estradiol into a custom cream is also bioidentical, but the product has not passed the same manufacturing controls.

The 2023 Menopause Society Position Statement states directly: "Commercially available, government-approved bioidentical hormones are preferred over custom-compounded hormones because of greater certainty about purity, potency, and safety." [1] That is the clinical anchor for this comparison.

Synthetic progestins (medroxyprogesterone acetate, norethindrone acetate) differ structurally from endogenous progesterone. Data from the Women's Health Initiative (WHI, N=16,608) showed that the combination of conjugated equine estrogens (CEE) plus medroxyprogesterone acetate (MPA) was associated with a small but statistically significant increase in breast cancer risk (hazard ratio 1.26 to 95% CI 1.00-1.59) at 5.6 years of follow-up. [2] By contrast, the estrogen-only arm of the WHI (women with prior hysterectomy) showed no increased breast cancer risk and trended toward a reduction. [3] The French E3N cohort (N=80,377) found that oral micronized progesterone paired with transdermal estradiol was not associated with increased breast cancer risk over 8 years, in contrast to synthetic progestin combinations. [4] These distinctions drive much of the clinical rationale for preferring bioidentical micronized progesterone over synthetic progestins.

FDA-Approved HRT: What the Label Guarantees

An FDA-approved hormone product has passed pre-market review for safety, efficacy, manufacturing quality (21 CFR Part 211), and accurate labeling. [5] Every batch is produced under Current Good Manufacturing Practice (cGMP) with validated potency and sterility testing. The dose you read on the box is what you get.

That reproducibility matters clinically. If a patch states it delivers 0.05 mg of estradiol per 24 hours, pharmacokinetic studies confirm that number. The NAMS 2022 Hormone Therapy Position Statement notes that transdermal estradiol products "deliver consistent serum estradiol levels with low interindividual variability." [6] Consistent serum levels translate to predictable symptom control and predictable risk profiles.

The approved product list for menopausal HRT in the United States includes:

• Oral estradiol (Estrace, generic 0.5-2 mg)
• Transdermal patches (Climara 0.025-0.1 mg/day, Vivelle-Dot 0.025-0.1 mg/day, Minivelle)
• Transdermal gels (Divigel 0.25-1.0 g packets, EstroGel 0.75 mg/pump)
• Transdermal spray (Evamist 1.53 mg/spray)
• Vaginal rings (Estring 7.5 mcg/day local; Femring 0.05-0.1 mg/day systemic)
• Vaginal cream/tablet/ring (Estrace cream, Vagifem, Imvexxy for GSM)
• Oral micronized progesterone (Prometrium 100 mg, 200 mg)
• Combination patches (CombiPatch estradiol/norethindrone acetate; Climara Pro)
• Conjugated equine estrogens (Premarin 0.3-1.25 mg oral, cream)
• Tissue-selective estrogen complex (Duavee: conjugated estrogens 0.45 mg / bazedoxifene 20 mg)

FDA approval also requires a black-box warning when evidence supports it. The current label warning on most systemic estrogen products reflects WHI data. That same evidence base does not exist for compounded products, so compounders are not required to include the same warnings, which can create a misleading impression of greater safety. [7]

Compounded HRT: Legitimate Uses and Real Risks

Compounding pharmacies are licensed to prepare customized medications under a physician's order. This fills real clinical gaps. A woman allergic to the peanut oil base in Prometrium can receive micronized progesterone in a different carrier. A patient needing 0.0375 mg estradiol (between the 0.025 mg and 0.05 mg patch options) may benefit from a compounded gel. Vaginal estriol, not available in an FDA-approved product in the United States, requires compounding and is widely used in Europe for genitourinary syndrome of menopause (GSM). [8]

The risks center on quality and consistency. A 2021 FDA analysis of compounded hormone preparations found that 34% of samples tested were out of specification for potency, some by more than 25%. [9] A separate study published in Menopause (Pinkerton et al., 2020) examined 30 commercially compounded progesterone preparations and found serum progesterone levels after ingestion were roughly 2.5-fold lower than with FDA-approved oral micronized progesterone at the same nominal dose. [10] Under-delivery of progesterone in a woman with a uterus leaves the endometrium under-opposed, raising hyperplasia risk.

Sterility failures at compounding pharmacies have caused documented patient harm. The 2012 New England Compounding Center (NECC) fungal meningitis outbreak sickened 793 people and caused 64 deaths. [11] That case involved pain injections, not HRT, but it illustrates what happens when cGMP standards are not enforced consistently.

The HealthRX clinical team uses the following framework to decide when compounding is warranted:

1. Medical necessity documented: an allergy to an inactive ingredient in all FDA-approved alternatives, or a required dose/route not commercially available.
2. PCAB-accredited pharmacy only: the pharmacy holds Pharmacy Compounding Accreditation Board accreditation and has passed independent potency testing within the past 12 months.
3. Specific written compounding order: not a pre-made "wellness panel" sold without an individualized assessment.
4. Serum hormone monitoring at 6-8 weeks: to verify the preparation is delivering the intended dose.

Outside those four criteria, an FDA-approved product is the default.

Oral vs Transdermal Estradiol: The Route Matters

This is one of the most clinically consequential decisions in HRT prescribing. Oral estradiol undergoes first-pass hepatic metabolism, driving up sex-hormone-binding globulin (SHBG), C-reactive protein, and clotting factors (factors VII, VIII, and fibrinogen). Transdermal estradiol bypasses the liver and produces almost none of those changes at therapeutic doses. [12]

The ESTHER study (N=881, case-control) found that oral estrogen was associated with a 4-fold increase in venous thromboembolism (VTE) risk compared to non-users, while transdermal estrogen was not associated with increased VTE risk (adjusted OR 0.9 to 95% CI 0.4-2.1). [13] For women with obesity, migraine with aura, or a personal history of DVT, transdermal estradiol is the preferred route per both the British Menopause Society and the Menopause Society. [6]

Oral estradiol does retain advantages. It is inexpensive (generic 1 mg tablets can cost under $15/month), easy to take, and produces stable trough-to-peak ratios that some women find produce steadier symptom relief. Oral estradiol at 1-2 mg/day also raises HDL cholesterol modestly, which may matter for some cardiovascular risk profiles, though that lipid effect does not translate to proven cardiovascular event reduction based on current trial data. [2]

Patch vs Gel Estradiol: Practical Differences

Both deliver estradiol transdermally, bypassing first-pass metabolism and producing comparable serum levels at equivalent doses. The clinical choice is mostly about lifestyle fit and skin tolerability.

Patches (Climara, Vivelle-Dot, Minivelle) adhere to the lower abdomen or buttock. Weekly (Climara) or twice-weekly (Vivelle-Dot) application reduces daily adherence burden. Adhesion problems occur in about 10-15% of patch users, particularly in humid climates or during intense exercise. Skin irritation at the application site is reported in roughly 14% of users across key trials, though most cases are mild. [14]

Gels (Divigel, EstroGel) are applied daily, most often to the thigh or upper arm. They dry within 2-5 minutes and leave no residue when used correctly. The transfer risk is real: a partner or child touching an unwashed application site within 1-2 hours can absorb measurable estradiol. The FDA issued a public health advisory on this in 2008. [15] Covering the site or washing hands thoroughly after application eliminates most of the transfer risk.

Dose equivalence is approximate: Vivelle-Dot 0.05 mg/day patch produces mean serum estradiol levels in the 40-60 pg/mL range, comparable to Divigel 0.5 g/day (0.5 mg estradiol). Both are adequate for hot flash suppression in most perimenopausal and postmenopausal women. A 2019 review in Climacteric (Stevenson et al.) confirmed that patches and gels produce "essentially equivalent endometrial safety and symptom relief when doses are titrated to similar serum estradiol levels." [16]

Pellets vs Patches: Why the Evidence Gap Matters

Subcutaneous testosterone and estradiol pellets have grown in popularity at medical spas and concierge practices. A pellet roughly the size of a grain of rice is inserted into the buttock or hip fat, releasing hormone over 3-6 months. Proponents cite steady hormone levels without daily adherence concerns.

The evidence base does not support pellets as a preferred HRT delivery method. No randomized controlled phase III trial has examined pellet-delivered estradiol against an FDA-approved comparator for efficacy or long-term safety. The pellet dose, once inserted, cannot be adjusted or removed if side effects occur. Supraphysiologic estradiol levels have been documented with pellet therapy, with some case series reporting serum estradiol levels above 300 pg/mL, compared to the physiologic premenopausal range of 30-400 pg/mL depending on cycle phase. Sustained supraphysiologic levels raise theoretical concerns about estrogen-sensitive tissue stimulation. [17]

The 2023 Menopause Society Position Statement does not endorse pellet therapy due to the absence of high-quality safety data and the inability to reverse dosing errors. [1] The British Menopause Society reached the same conclusion in its 2022 recommendations. The FDA has not approved any pellet product for menopausal hormone therapy in women; all female pellet implants are compounded.

Insertion-site complications (infection, extrusion, scarring) occur in approximately 1-3% of procedures based on retrospective series, and the financial cost per insertion ($300-$500 every 3-5 months at most clinics) substantially exceeds the cost of an FDA-approved patch or gel regimen. For these reasons, the HealthRX medical team does not prescribe pellet therapy for women's HRT.

Progesterone: Bioidentical Micronized vs Synthetic Progestins vs Compounded

Women who have a uterus and take systemic estrogen require progestogen to protect the endometrium from unopposed estrogen stimulation. The choice of progestogen has meaningful safety implications.

Oral micronized progesterone (Prometrium 100-200 mg) is FDA-approved, bioidentical in structure, and supported by the largest independent European safety dataset. The E3N cohort showed no statistically significant increase in breast cancer risk with estradiol plus micronized progesterone after 8 years of follow-up (RR 1.00 to 95% CI 0.83-1.22), compared to RR 1.69 (95% CI 1.50-1.91) for estradiol plus synthetic progestin. [4]

Synthetic progestins (MPA in Prempro, norethindrone acetate in CombiPatch) have stronger endometrial protection data from long-term trials but carry the breast cancer risk signal from the WHI. [2] They may still be appropriate for women who cannot tolerate micronized progesterone or who have cost constraints (generic Prempro is less expensive than brand Prometrium).

Compounded progesterone in topical cream form is popular but pharmacokinetically unreliable. Progesterone is poorly absorbed through skin. Studies using transvaginal ultrasound have confirmed that topical compounded progesterone creams do not consistently suppress endometrial proliferation at typical compounded doses (20-40 mg/day), creating real endometrial hyperplasia risk in women taking systemic estrogen. [10] Compounded vaginal progesterone suppositories achieve better absorption than creams but are not a substitute for validated FDA-approved regimens without monitoring.

Saliva and Urine Testing for Hormone Levels: Clinical Value Is Limited

Compounding-oriented practices frequently market comprehensive hormone panels using saliva or dried urine testing (DUTCH test) as the basis for customized hormone prescriptions. The Menopause Society and the Endocrine Society do not endorse saliva testing for guiding HRT dosing. [18] Saliva hormone levels fluctuate by 30-40% across a single day, vary with oral hygiene, and do not reliably reflect tissue hormone activity.

Serum estradiol, FSH, and progesterone (day 21 serum for progesterone adequacy) remain the validated monitoring tools. A morning fasting serum estradiol drawn 12-24 hours after the last patch change or gel application gives a useful trough level. Target trough estradiol for symptom relief is typically 40-100 pg/mL in most clinical protocols, though individual response varies. [6]

How to Choose: A Decision Path

Start with your uterus status and risk profile:

No uterus (prior hysterectomy): Estrogen alone. Transdermal is preferred if any cardiovascular risk factors, obesity (BMI >30), migraine with aura, or VTE history are present. Oral estradiol or CEE is acceptable for low-risk women who prefer a pill. No progestogen needed.

Uterus intact: Estrogen plus progestogen. First-line is transdermal estradiol (patch or gel) plus oral micronized progesterone 100-200 mg nightly. FDA-approved products for both are readily available and the evidence base is solid.

GSM only (vaginal dryness, painful intercourse, urinary urgency): Low-dose vaginal estradiol (Vagifem 10 mcg, Imvexxy 4-10 mcg, Estring 7.5 mcg/day ring) is the preferred option. Systemic absorption is minimal and progestogen is generally not required. Compounded vaginal estriol is a reasonable alternative if a patient has a documented preference or cost barrier, given the favorable European safety record of estriol, but no FDA-approved estriol product exists in the US.

Legitimate reason to compound: Allergy to inactive ingredients in all approved alternatives, need for a dose or ratio not commercially available, or confirmed PCAB-accredited pharmacy with potency verification. These situations exist; they are just less common than compounding marketing suggests.

Cost and Insurance Reality

FDA-approved generic estradiol patches (Mylan, Actavis) cost $15-45/month at most retail pharmacies and are covered by most commercial insurance plans and Medicare Part D. Generic oral estradiol 1 mg costs under $10/month at GoodRx prices at major chains. Prometrium 100 mg (30 capsules) runs $30-80/month depending on pharmacy and insurance.

Compounded HRT is almost never covered by insurance and typically costs $50-200/month depending on formulation and pharmacy. Pellet insertions ($300-500 per session, 2-4 times per year) represent the highest out-of-pocket cost option with the weakest evidence base.